All In Biotech

Drug Trial Radar · NCT01843348

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certican® Based Regimen Either in Combination With Cyclosporin A or Tacrolimus

Last checked: Nov 20, 2026Latest source record: May 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

612

Actual

Start

Dec 27, 2012

Primary completion

Mar 23, 2016

Study completion Mar 23, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the renal function comparing Certican based immunosuppressive regimens with two different CNIs (Tacrolimus or Cyclosporin A) versus a standard treatment with Mycophenolic Acid and Tacrolimus in de novo renal transplant recipients.

Conditions

  • Kidney Transplantation
  • Renal Transplantation

Interventions

  • EverolimusDrug

  • TacrolimusDrug

    Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels

  • Cyclosporin ADrug

    Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml

  • Enteric Coated Mycophenolate Sodium (EC-MPS)Drug

    Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose

  • Mycophenolate mofetil (MMF)Drug

    Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose

  • CorticosteroidsDrug

    A minimum dose of 5 mg prednisolon or equivalent

  • SimulectDrug

    Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican RegimensTime frame: One year post transplant

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Saint-Priest-en-Jarez, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Poitiers, France, France

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.